A new initiative with the bone fusion solution ‘NOVOSIS’ is underway in Indonesia.
CGBio (CEO Hyun-Seung Yu), a company specialized in regenerative medicine, recently held a global academic symposium, ‘Meet the Experts’, targeting orthopedic surgeons in Indonesia. The event highlighted various case studies and suggested potential expansions in indications for the bone substitute ‘NOVOSIS’, which has garnered significant attention.
The ‘Meet the Experts’ symposium was attended by 30 Indonesian orthopedic surgeons and was organized to share case studies and techniques using NOVOSIS, which contains recombinant human Bone Morphogenetic Protein-2 (rhBMP-2). Unlike previous events focused on sharing and learning about Korean medical technologies, this symposium had significant implications as it centered on discussing and sharing the innovative uses of NOVOSIS by Indonesian medical professionals based on their accumulated case experiences.
Hosted by CGBio, the ‘Meet the Experts’ symposium aims to disseminate superior Korean medical technologies globally. It provides a platform for global specialists to share case studies and the latest insights and to learn surgical techniques that can aid in actual patient care. This is part of CGBio’s strategy of open collaboration, which has been sharing various patient treatment cases from countries like Thailand, Vietnam, Indonesia, India, and Singapore.
Noticing the high growth potential in the Indonesian medical device market, CGBio launched NOVOSIS in 2021, entering the Indonesian bone graft market. The company has increased medical professionals’ understanding through academic seminars targeting specialists, which has gradually expanded its use, showing positive treatment outcomes in spinal fusion and fracture union surgeries caused by trauma.
At this year’s ‘Meet the Experts’, clinically significant results were shared, including cases applying NOVOSIS in patients expected to experience non-union or delayed union, such as those with Avascular Necrosis Syndrome (AVN). Primarily in diseases where therapeutic alternatives are few or lacking, new applications of NOVOSIS were suggested, and these experiences indicate the potential for future expansion into new indications.
The symposium was chaired by Professor Ismail Hadisoebroto Dilogo of Cipto Mangunkusumo Hospital, Jakarta, with presentations on the application of NOVOSIS in trauma and joint reconstruction, periprosthetic fractures, and hip avascular necrosis.
The symposium featured presentations from several distinguished speakers. Professor Jo Min-jun of Boramae Hospital, Seoul, discussed the efficacy and safety of NOVOSIS in lumbar fusion surgery. Professor I Gusti Lanang Ngurah Agung Artha Wiguna of Siloam Hospitals highlighted the application of NOVOSIS in cervical surgery. Professor Park Young-hwan of Korea University Guro Hospital shared insights into the clinical application of NOVOSIS in foot and ankle surgery. Finally, Professor Cho Won-tae of Ajou University Hospital explored the use of NOVOSIS in treating elderly patients with fracture-related bone defects.
This event allowed medical professionals currently using NOVOSIS to learn various surgical techniques and patient cases that aid in treatment and provided an opportunity for those new to the product to recognize its necessity and justification.
Following this symposium, CGBio plans to conduct research on newly developed indications and clinical trials in active collaboration with local medical professionals, laying the clinical groundwork for global market expansion. Moreover, it aims to expand its influence beyond Indonesia to other countries through global networking opportunities, thereby increasing its global market share.
“Bringing orthopedic specialists together at this symposium to share innovative insights and treatment cases concerning NOVOSIS was truly meaningful,” said Hyun-Seung Yu, CEO of CGBio. “Moreover, we anticipate that the launch of a high-dose NOVOSIS (1mg) by the end of this year will enhance usability locally and actively explore further expanded indication cases.”
▲ Professor Ismail Hadisoebroto Dilogo from Indonesia is presenting at the CGBio ‘Meet the Experts’
▲ Professor I Gusti Lanang Ngurah Agung Artha Wiguna from Indonesia is presenting at the CGBio ‘Meet the Experts’
▲ Product image of CGBio’s bone substitute ‘NOVOSIS’
